Clinical cancer research : an official journal of the American Association for Cancer Research
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trial.
Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, Ivan Valiev, Amaury Leruste, Nicolas André, Dominique Bluteau, Nadege Corradini, Jonathan Rubino, Fabienne Thomas, Souad Nebchi, Eleni Karamouza, Jeanne Petit, Estelle Thebaud, Alba Rubio-San-Simón
Published: 202610.1158/1078-0432.CCR-25-3767
Abstract
PURPOSE: Arm D of the AcSé-ESMART proof-of-concept phase I/II platform trial aimed to define the recommended phase II dose (RP2D), pharmacokinetics, activity, and biomarkers of the PARP inhibitor olaparib with irinotecan in pediatric patients with re…
Preview only. Read the full abstract at the source